Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

Authors

  • Juul M.P.A. van den Reek
  • Lieke J. van Vugt
  • Martijn B.A. van Doorn
  • Gayle E. van der Kraaij
  • Wim J.A. de Kort
  • Georges P.H. Lucker
  • Barbara Horvath
  • M. David Njoo
  • H. Jorn Bovenschen
  • Paul M. Ossenkoppele
  • Marjolein S. De Bruin-Weller
  • Marjan de Groot
  • Roland Mommers
  • Ruud L.M.A. Prevoo
  • Peter C.M. van de Kerkhof
  • Phyllis I. Spuls
  • Wietske Kievit
  • Elke M.G.J. de Jong

DOI:

https://doi.org/10.2340/00015555-2900

Keywords:

psoriasis, secukinumab, biologics, drug survival, effectiveness.

Abstract

Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily practice. The aim of this study was to evaluate drug survival of secukinumab in a daily practice psoriasis cohort. Data were collected from 13 hospitals. Drug survival was analysed using Kaplan?Meier survival curves, split for reason of discontinuation. In total, 196 patients were included (83% biologic experienced). Overall, 12 and 18 months drug survival of secukinumab was 76% and 67%, respectively, and was mostly determined by ineffectiveness. There was a trend towards shorter drug survival in women and in biologic experienced patients. Thirteen percent of patients experienced at least one episode of fungal infection. This is one of the first studies of drug survival of secukinumab in patients with psoriasis treated in daily practice.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2018-04-12

How to Cite

van den Reek, J. M., van Vugt, L. J., van Doorn, M. B., van der Kraaij, G. E., de Kort, W. J., Lucker, G. P., Horvath, B., Njoo, M. D., Bovenschen, H. J., Ossenkoppele, P. M., De Bruin-Weller, M. S., de Groot, M., Mommers, R., Prevoo, R. L., van de Kerkhof, P. C., Spuls, P. I., Kievit, W., & de Jong, E. M. (2018). Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study. Acta Dermato-Venereologica, 98(7), 648–654. https://doi.org/10.2340/00015555-2900

Issue

Vol. 98 No. 7 (2018): July

Section

Articles

License

Copyright (c) 2018 Juul M.P.A. van den Reek, Lieke J. van Vugt, Martijn B.A. van Doorn, Gayle E. van der Kraaij, Wim J.A. de Kort, Georges P.H. Lucker, Barbara Horvath, M. David Njoo, H. Jorn Bovenschen, Paul M. Ossenkoppele, Marjolein S. De Bruin-Weller, Marjan de Groot, Roland Mommers, Ruud L.M.A. Prevoo, Peter C.M. van de Kerkhof, Phyllis I. Spuls, Wietske Kievit, Elke M.G.J. de Jong

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC